glp 1 for dementia Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease In New Dementia Trials, Ozempic's

semaglutide has balanced signaling Weight loss : Comparable Phase 3 results (~15%), but different populations and durations Evidence base : Semaglutide has 25,000+ patients and 7+ years

Some semaglutide programs include B12 in the compounded formulation specifically because of the increased risk of deficiency

Feel free to reach out via email at [email protected] for a friendly chat

Popular brands of these anti-diabetes and anti-obesity drugs include Ozempic, Wegovy and Mounjaro

Given that GLP-1RAs are demonstrating efficacy in diseases beyond weight loss and diabetes, their use is only going to increase

They can bring a targeted expertise that is often missed in primary care conversations